Opposing Effects of PI3K/Akt and Smad-Dependent Signaling Pathways in NAG-1-Induced Glioblastoma Cell Apoptosis

Nonsteroidal anti-inflammatory drug (NSAID) activated gene-1 (NAG-1) is a divergent member of the transforming growth factor-beta (TGF-β) superfamily. NAG-1 plays remarkable multifunctional roles in controlling diverse physiological and pathological processes including cancer. Like other TGF-β family members, NAG-1 can play dual roles during cancer development and progression by negatively or positively modulating cancer cell behaviors. In glioblastoma brain tumors, NAG-1 appears to act as a tumor suppressor gene; however, the precise underlying mechanisms have not been well elucidated. In the present study, we discovered that overexpression of NAG-1 induced apoptosis in U87 MG, U118 MG, U251 MG, and T98G cell lines via the intrinsic mitochondrial pathway, but not in A172 and LN-229 cell lines. NAG-1 could induce the phosphorylation of PI3K/Akt and Smad2/3 in all six tested glioblastoma cell lines, except Smad3 phosphorylation in A172 and LN-229 cell lines. In fact, Smad3 expression and its phosphorylation were almost undetectable in A172 and LN-229 cells. The PI3K inhibitors promoted NAG-1-induced glioblastoma cell apoptosis, while siRNAs to Smad2 and Smad3 decreased the apoptosis rate. NAG-1 also stimulated the direct interaction between Akt and Smad3 in glioblastoma cells. Elevating the level of Smad3 restored the sensitivity to NAG-1-induced apoptosis in A172 and LN-229 cells. In conclusion, our results suggest that PI3K/Akt and Smad-dependent signaling pathways display opposing effects in NAG-1-induced glioblastoma cell apoptosis.

[1]  Jianlin Yuan,et al.  Adaptive Induction of Growth Differentiation Factor 15 Attenuates Endothelial Cell Apoptosis in Response to High Glucose Stimulus , 2013, PloS one.

[2]  Tinghong Ye,et al.  A Novel Benzothiazole Derivative YLT322 Induces Apoptosis via the Mitochondrial Apoptosis Pathway In Vitro with Anti-Tumor Activity in Solid Malignancies , 2013, PloS one.

[3]  A. Sami,et al.  Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding , 2013, Tumor Biology.

[4]  S. Baek,et al.  The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. , 2013, Biochemical pharmacology.

[5]  P. Russell,et al.  Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15) Slows Cancer Development but Increases Metastases in TRAMP Prostate Cancer Prone Mice , 2012, PloS one.

[6]  J. Jeruss,et al.  Phospho-specific Smad3 signaling , 2012, Cell cycle.

[7]  H. Kamitani,et al.  DNA methylation‐mediated silencing of nonsteroidal anti‐inflammatory drug‐activated gene (NAG‐1/GDF15) in glioma cell lines , 2012, International journal of cancer.

[8]  M. Mimeault,et al.  Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine‐1 in cancer , 2010, Journal of cellular physiology.

[9]  S. K. Choudhuri,et al.  Targeting Mitochondrial Cell Death Pathway to Overcome Drug Resistance with a Newly Developed Iron Chelate , 2010, PloS one.

[10]  R. Stupp,et al.  Elevated levels of MIC‐1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome , 2009, International journal of cancer.

[11]  H. Grönberg,et al.  Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer , 2009, Clinical Cancer Research.

[12]  C. Arvanitis,et al.  Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells , 2009, British Journal of Cancer.

[13]  H. Kamitani,et al.  Nonsteroidal Anti-inflammatory Drug-activated Gene (NAG-1/GDF15) Expression Is Increased by the Histone Deacetylase Inhibitor Trichostatin A* , 2008, Journal of Biological Chemistry.

[14]  M. Weller,et al.  Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. , 2008, Cancer letters.

[15]  Jung Joon Lee,et al.  Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. , 2008, Carcinogenesis.

[16]  S. Baek,et al.  NSAID activated gene (NAG-1), a modulator of tumorigenesis. , 2006, Journal of biochemistry and molecular biology.

[17]  J. Seoane.  Escaping from the TGFβ anti-proliferative control , 2006 .

[18]  A. Nakao,et al.  Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor. , 2006, Journal of neurosurgery.

[19]  H. Johnen,et al.  Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. , 2006, Cancer research.

[20]  Yingdong Zhao,et al.  Common cancer biomarkers. , 2006, Cancer research.

[21]  J. Seoane.  Escaping from the TGFbeta anti-proliferative control. , 2006, Carcinogenesis.

[22]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[23]  D. Morrish,et al.  PL74, a novel member of the transforming growth factor-beta superfamily, is overexpressed in preeclampsia and causes apoptosis in trophoblast cells. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  K. Luo,et al.  Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis , 2004, Nature Cell Biology.

[25]  Stephen W. Michnick,et al.  PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3 , 2004, Nature Cell Biology.

[26]  K. Kinzler,et al.  Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers , 2004, Clinical Cancer Research.

[27]  S. Michnick,et al.  PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. , 2004, Nature cell biology.

[28]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[29]  S. Baek,et al.  Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. , 2001, Molecular pharmacology.

[30]  K. Guan,et al.  PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway , 2000 .

[31]  K. Guan,et al.  PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Unsicker,et al.  Expression of a novel member of the TGF-β superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues , 1999, Cell and Tissue Research.

[33]  C. Heldin,et al.  Expression of transforming‐growth‐factor (TGF)‐β receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF‐β1 , 1999 .

[34]  C. Heldin,et al.  Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1. , 1999, International journal of cancer.

[35]  S. Vukicevic,et al.  Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family* , 1998, The Journal of Biological Chemistry.

[36]  M. Soares,et al.  Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. , 1997, Gene.

[37]  W. D. Fairlie,et al.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Hromas,et al.  PLAB, a novel placental bone morphogenetic protein. , 1997, Biochimica et biophysica acta.